Results 81 to 90 of about 114,162 (186)

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus, J. David Smeijer, Phil Ambery, Peter J. Greasley, Emma Wijkmark, David C. Wheeler, Peter Rossing, Hiddo J. L. Heerspink   +7 more
wiley   +1 more source

Renal cell carcinoma in autosomal dominant polycystic kidney disease: A case report

Radiology Case Reports, 2023
Autosomal dominant polycystic kidney disease (ADPKD) is one of the congenital cystic renal diseases with the highest incidence. ADPKD was suspected of being a risk factor for the emergence of RCC.
Gullyawan Rooseno, Ida Bagus Gde Tirta Yoga Yatindra, Wahjoe Djatisoesanto, Tarmono Djojodimedjo   +3 more
doaj  

New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol [PDF]

, 2015
Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder with numerous cysts developing in bilateral kidneys.
Ajabnoor, Barua, de Mattos, Guyatt, Harris, Hernández-Fisac, Kanaan, Kidney Disease: Improving Global Outcomes Transplant Work Group, Mao, McCarthy, Menon, Moher, Oetjen, Perrone, Pietrzak-Nowacka, Pietrzak-Nowacka, Pietrzak-Nowacka, Ruderman, Shamseer, Torra, Torres, Torres, Turkmen   +22 more
core   +1 more source

A Novel Inhibitor of Methyltransferase SMYD2, AZ505 Protects Against Peritoneal Fibrosis in Mice

Clinical and Experimental Pharmacology and Physiology, Volume 52, Issue 7, July 2025.
AZ505, a highly selective inhibitor of SMYD2, may exhibit an antifibrotic effect in peritoneal fibrosis. ABSTRACT AZ505, a highly selective inhibitor of SMYD2, exhibits an antifibrotic effect in renal fibrosis. Its effect on peritoneal fibrosis remains unexplored.
Taijing Xu, Binbin Cui, Feng Liu, Mengjun Liu, Xiying Hou, Xuan Hong, Hualin Qi   +6 more
wiley   +1 more source

Autopsy Report with Clinical and Pathophysiologic Discussion of Autosomal Dominant Adult Polycystic Kidney Disease

Case Reports in Urology, 2014
The average weight of a kidney is approximately 135 gm, measuring on average 10 × 6 × 4 cm. In hereditary conditions, autosomal dominant and autosomal recessive polycystic kidney disease, the shape, size, and the weight can be significantly abnormal ...
Anup Hazra, Richard Siderits, Cheryl Rimmer, Noah Rolleri   +3 more
doaj   +1 more source

Inference and Prediction Using Functional Principal Components Analysis: Application to Diabetic Kidney Disease Progression in the Chronic Renal Insufficiency Cohort (CRIC) Study [PDF]

arXiv, 2022
Repeated longitudinal measurements are commonly used to model long-term disease progression, and timing and number of assessments per patient may vary, leading to irregularly spaced and sparse data. Longitudinal trajectories may exhibit curvilinear patterns, in which mixed linear regression methods may fail to capture true trends in the data.
arxiv  

Renin-Angiotensin-Aldosterone System Antagonism and Polycystic Kidney Disease Progression. [PDF]

, 2016
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a systemic disease characterised by the formation of multiple renal cysts that adversely affect renal function.
Hian, Chuan Kai, Lee, Chin Liang, Thomas, Warren   +2 more
core   +2 more sources

The Vertebrate Breed Ontology: Toward Effective Breed Data Standardization

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT Background Limited universally‐adopted data standards in veterinary medicine hinder data interoperability and therefore integration and comparison; this ultimately impedes the application of existing information‐based tools to support advancement in diagnostics, treatments, and precision medicine.
Kathleen R. Mullen, Imke Tammen, Nicolas A. Matentzoglu, Marius Mather, James P. Balhoff, Elizabeth Esdaile, Gregoire Leroy, Carissa A. Park, Halie M. Rando, Nadia T. Saklou, Tracy L. Webb, Nicole A. Vasilevsky, Christopher J. Mungall, Melissa A. Haendel, Frank W. Nicholas, Sabrina Toro   +15 more
wiley   +1 more source

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care [PDF]

, 2017
Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterised by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
Alastair Kent, Albert C M Ong, Brenda de Coninck, Denis Clément, Dorien Peters, Elena Levtchenko, Hendrik Van Poppel, Joost P H Drenth, José Luis Górriz, Klemens Budde, Lorenzo E Derchi, Marianna Eleftheroudi, null null, null null, null null, Olivier Devuyst, Raymond Vanholder, Richard Sandford, Ron T Gansevoort, Tess Harris, Tevfik Ecder, Vicente E Torres, Yves Pirson   +22 more
core   +6 more sources

Elucidating the Molecular Landscape of Cystic Kidney Disease: Old Friends, New Friends and Some Surprises

American Journal of Medical Genetics Part A, Volume 197, Issue 6, June 2025.
ABSTRACT Cystic kidney diseases (CyKD) are a diverse group of disorders affecting more than 1 in 1000 individuals. Over 120 genes are implicated, primarily encoding components of the primary cilium, transcription factors, and morphogens. Prognosis varies greatly by molecular diagnosis. Causal variants are not identified in 10%–60% of individuals due to
Deborah Watson, Frank Mentch, Jonathan Billings, Kayleigh Ostberg, Michael E. March, Jennifer M. Kalish, Dong Li, India Cannon, Lisa M. Guay‐Woodford, Erum Hartung, Alanna Strong   +10 more
wiley   +1 more source